Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8N5J2
UPID:
MINY1_HUMAN
Alternative names:
Deubiquitinating enzyme MINDY-1; Protein FAM63A
Alternative UPACC:
Q8N5J2; B3KWP4; B3KWV8; B4DXF2; B4E1S4; D3DV09; J3KP53; Q5SZF0; Q9NUL9; Q9P2F7
Background:
Ubiquitin carboxyl-terminal hydrolase MINDY-1, also known as Deubiquitinating enzyme MINDY-1 or Protein FAM63A, plays a crucial role in protein turnover. It is a hydrolase that specifically targets 'Lys-48'-linked conjugated ubiquitin, preferring long polyubiquitin chains for removal from proteins. This activity suggests a regulatory function in the degradation and recycling of proteins.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase MINDY-1 could open doors to potential therapeutic strategies. Its unique ability to process long polyubiquitin chains positions it as a key player in maintaining cellular protein homeostasis, a process often disrupted in diseases.